Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Genetics of Rolandic Epilepsy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2011 by King's College London.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Information provided by:
King's College London
ClinicalTrials.gov Identifier:
NCT00282854
First received: January 26, 2006
Last updated: December 5, 2011
Last verified: August 2011
  Purpose

The purpose of this study is to find the genes that cause Rolandic epilepsy and its related traits.


Condition
Epilepsy

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Genetics of Rolandic Epilepsy

Resource links provided by NLM:


Further study details as provided by King's College London:

Biospecimen Retention:   Samples With DNA

whole blood


Estimated Enrollment: 1000
Study Start Date: January 2005
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
Group I: Cases
Children with rolandic epilepsy
Group II: Controls
Individuals group matched to cases for ethnicity, sex and area of residence but lacking a primary brain disorder.

Detailed Description:

Rolandic epilepsy (RE) is the most common type of childhood epilepsy—affecting more than 50,000 children in the United States—and has a complex genetic inheritance. The seizure prognosis is relatively benign, however, many children with RE also have problems with speech and language, reading, and motor coordination. Symptoms of the disorder overlap with more severe types of epilepsy.

The purpose of this study is to find the genes that influence RE and its related traits. Identifying genetic causes for the variants would improve diagnosis and allow for early intervention.

Researchers will enroll 1000 children with RE and 3000 controls for participation in the study. The scientists will request medical histories and (salivary) DNA samples from the participants. Participation can be completed by mail and telephone.

Results from this study should provide important information regarding diagnosis and prognosis of RE, may be useful in clinical management, and, eventually, may lead to a cure for this and other forms of epilepsy.

  Eligibility

Ages Eligible for Study:   3 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Community Sample

Criteria

Inclusion:

  • typical history of focal seizures
  • EEG centrotemporal sharp waves
  • age of onset 3-12 years
  • no previous epilepsy type (febrile seizures OK)
  • normal development
  • normal neurological examination
  • normal MRI/CT (if done)

Exclusion:

  • only history of secondary generalized seizures
  • atypical history/semiology
  • history and EEG inconsistent
  • abnormal EEG background
  • very early (<3yrs) or late (>12yrs) onset
  • global neurodevelopmental deficit
  • deviant neurodevelopment
  • structural imaging abnormality
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00282854

Contacts
Contact: Deb Pal, MD, PhD 212 342 1237 dkp28@columbia.edu

Locations
United States, New York
Mailman School of Public Health, Columbia University Medical Center, 722 West 168th St, 6th Floor Recruiting
New York, New York, United States, 10032
Contact: Deb Pal, MD, PhD    212-342-1237    dkp28@columbia.edu   
Sponsors and Collaborators
King's College London
Investigators
Principal Investigator: Deb K. Pal, MD, PhD Associate Research Scientist, Mailman School of Public Health, Columbia University Medical Center
  More Information

Additional Information:
No publications provided

Responsible Party: Deb K Pal MD PHD, Columbia University
ClinicalTrials.gov Identifier: NCT00282854     History of Changes
Other Study ID Numbers: 4727, R01NS047530
Study First Received: January 26, 2006
Last Updated: December 5, 2011
Health Authority: United States: Federal Government

Keywords provided by King's College London:
epilepsy
Rolandic epilepsy

Additional relevant MeSH terms:
Epilepsy
Epilepsy, Rolandic
Brain Diseases
Central Nervous System Diseases
Epilepsies, Partial
Nervous System Diseases

ClinicalTrials.gov processed this record on November 20, 2014